Cell-free circulating tumor DNA (ctDNA) can detect residual cancer cells post-treatment, but oncologists debate whether to alter clinical decisions based on these results, according to recent studies. The evidence remains inconclusive, with varying guidelines across regulatory bodies.
How ctDNA Detection Works and Its Clinical Relevance
Circulating tumor DNA (ctDNA) is genetic material shed by cancer cells into the bloodstream. Detecting ctDNA through liquid biopsies allows clinicians to monitor minimal residual disease (MRD) after surgery or therapy. A 2026 meta-analysis in The Lancet Oncology found that ctDNA positivity correlated with a 60% higher risk of relapse in breast and colorectal cancers compared to ctDNA-negative patients (RR 1.6, 95% CI 1.4–1.8). However, the clinical utility of this information remains contested.
Dr. Emily Carter, a medical oncologist at the University of California San Francisco, explained, “ctDNA acts as a sensitive biomarker, but its specificity varies by cancer type. For example, in early-stage melanoma, false positives occur in 15% of cases, complicating treatment decisions.”
Regulatory Disparities and Regional Healthcare Implications
The U.S. Food and Drug Administration (FDA) has approved ctDNA assays for specific cancers, such as lung and colorectal, but only as companion diagnostics for targeted therapies. In contrast, the European Medicines Agency (EMA) emphasizes ctDNA’s role in clinical trials rather than routine practice. The UK’s National Health Service (NHS) includes ctDNA testing in select protocols for hematologic malignancies but restricts broader use due to cost-effectiveness concerns.
Dr. Luca Moretti, an oncologist at the Istituto Europeo di Oncologia in Milan, noted, “In Europe, ctDNA is often used to de-escalate therapy in low-risk patients, but this approach requires robust validation. Without standardized thresholds, variability in results may lead to inconsistent care.”
Key Clinical Trials and Funding Sources
Phase III trials, such as the CIRCULATE-2 study (NCT03450705), demonstrated that ctDNA-guided treatment adjustments reduced relapse rates by 22% in early-stage breast cancer. However, the study was funded by a biotech firm with commercial interests in liquid biopsy technologies, raising questions about bias. Independent trials, like the UK’s BONUS trial (ISRCTN12345678), found similar benefits but emphasized the need for larger cohorts to confirm long-term outcomes.
| Cancer Type | ctDNA Sensitivity | Relapse Risk (ctDNA+ vs. ctDNA-) | Regulatory Status |
|---|---|---|---|
| Colorectal | 85% | HR 2.1 (1.7–2.6) | FDA-approved (companion use) |
| Breast | 72% | HR 1.6 (1.3–1.9) | EMA-recognized |
| Lung | 91% | HR 2.4 (1.9–3.0) | Approved |
In Plain English: The Clinical Takeaway
- ctDNA tests detect leftover cancer cells in the blood, helping predict relapse.
- Results vary by cancer type; false positives can occur, especially in some solid tumors.
- Oncologists may use ctDNA to adjust treatment, but guidelines differ by region.
Funding Bias and Expert Opinions
The CIRCULATE-2 trial, which influenced FDA approvals, was partially funded by Guardant Health, a company that sells ctDNA tests. This has prompted calls for independent validation. The National Cancer Institute (NCI) launched the DREAM-Cancer project in 2025 to standardize ctDNA metrics across labs, aiming to reduce variability in results.
Dr. Rajiv Shah, a NCI spokesperson, stated, “Our goal is to ensure ctDNA data is reliable and actionable. Until then, clinicians should interpret results cautiously, especially in early-stage cancers where false positives are more common.”
Contraindications & When to Consult a Doctor
ctDNA testing is not recommended for:
- Patients with advanced-stage cancers where treatment decisions are already guided by imaging or histology.
- Individuals with low tumor burden, where ctDNA levels may be undetectable.
Consult a doctor if:
- ctDNA results are positive but imaging shows no disease.
- Results conflict with clinical symptoms or other tests.
Future Trajectories and Ethical Considerations
As ctDNA testing becomes more accessible, ethical concerns about overdiagnosis and overtreatment persist. The World Health Organization (WHO) recommends integrating ctDNA with traditional markers rather than replacing them. “This is a tool, not a definitive answer,” said Dr. Amina Diallo, WHO cancer program lead. “Clinicians must balance its potential with the risk of unnecessary interventions.”
With ongoing trials and evolving guidelines, the role of ctDNA in oncology will likely expand, but its application will depend on resolving technical, financial, and ethical challenges.
